Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 1/2 4Phase 2 3Phase 3 2

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3CNS 1

Conditions

Lymphoma 27Lymphoma, Non-Hodgkin 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Mantle-Cell 23Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Recurrence 13Hodgkin Disease 12Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 4Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Small Cell Lung Carcinoma 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Sarcoma 1Renal Insufficiency, Chronic 1

Interventions

Rituximab 45Cyclophosphamide 34Doxorubicin 16fludarabine 14Prednisone 14Vincristine 13Etoposide 13ibrutinib 10Mycophenolic Acid 8Bortezomib 8Magnetic Resonance Spectroscopy 7Lenalidomide 7Cytarabine 7pembrolizumab 6Immunotherapy, Adoptive 6polatuzumab vedotin 5fludarabine phosphate 5Whole-Body Irradiation 5Vorinostat 5Tacrolimus 5Specimen Handling 5CT-P10 5obinutuzumab 4ibritumomab tiuxetan 4Nivolumab 4Ifosfamide 4Carmustine 4Carboplatin 4Antilymphocyte Serum 4tafasitamab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell × Bendamustine Hydrochloride × Clear all
NCT07593482 2026-05-18

FC-BALANCE

Swiss Cancer Institute

Phase 2 Not yet recruiting
92 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Miltenyi Biomedicine GmbH

Phase 2 Recruiting
248 enrolled
CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT06415708 2024-05-16

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
134 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡